<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483936</url>
  </required_header>
  <id_info>
    <org_study_id>OLCEMS0215</org_study_id>
    <nct_id>NCT02483936</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control</brief_title>
  <official_title>Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two
      different drug associations in the essential hypertension control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of essential hypertension control based on the reduction of systolic blood pressure at the end of the study.</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>9 weeks</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Test 1: Olmesartan+Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2: Olmesartan+Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 1: Benicar HCT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 2: Benicar HCT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil 40mg + chlorthalidone 12,5mg</intervention_name>
    <description>1 tablet a day</description>
    <arm_group_label>Test 1: Olmesartan+Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil 40mg + chlorthalidone 25mg</intervention_name>
    <description>1 tablet a day</description>
    <arm_group_label>Test 2: Olmesartan+Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan 40mg + Hydrochlorothiazide 12,5mg</intervention_name>
    <description>1 tablet a day</description>
    <arm_group_label>Comparator 1: Benicar HCT®</arm_group_label>
    <other_name>Benicar HCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan 40mg + Hydrochlorothiazide 25mg</intervention_name>
    <description>1 tablet a day</description>
    <arm_group_label>Comparator 2: Benicar HCT®</arm_group_label>
    <other_name>Benicar HCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Consent of the patient;

          -  Participants with decompensated essential hypertension, classified into stage 1 (with
             high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian
             Society of Cardiology (2010), who are being treated with monotherapy.

        Exclusion Criteria:

          -  Patients with any clinically significant disease that in the investigator opinion can
             not participate in the study;

          -  Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the
             screening/randomization visit;

          -  Morbid obesity or immunocompromised patients;

          -  Participants with greater than 10 mmHg difference in the measurements of systolic or
             diastolic blood pressure between the two arms;

          -  Participants who do not have the two upper limbs;

          -  Participants with important electrocardiographic changes;

          -  Creatinine clearance - less than 60 mL / min;

          -  History of hypertensive emergencies and cardiovascular and / or moderate to severe
             cerebrovascular events in the past 6 months;

          -  Microalbuminuria urine sample greater than 30 mg/g;

          -  Patients with history of hypersensitivity to any of the formula compounds;

          -  Pregnancy or risk of pregnancy and lactation patients;

          -  Participation in clinical trial in the year prior to this study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B. Oliveira, M.D.</last_name>
    <phone>55</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

